Jim Krenn has extensive experience representing public and private companies and investors in corporate and securities matters. Mr. Krenn structures, negotiates and advises clients on a wide variety of financing and acquisition transactions and general corporate matters.
Mr. Krenn has represented clients in over $1 billion in equity and debt financings ranging from seed rounds to $100 million plus later stage rounds. He has also represented buyers and sellers in acquisitions and divestitures ranging from $1 million to over $1 billion, including stock purchases, asset purchases, mergers, tender offers, acquisitions and divestitures of divisions and subsidiaries, cross-border transactions and auction transactions.
Mr. Krenn counsels private and public companies on a broad range of significant business transactions from formation through liquidity, including private financings, public securities offerings, mergers and acquisitions and SEC compliance and reporting. Mr. Krenn also advises angel, corporate and venture capital investors in connection with investments, as well as liquidity and exit strategies. In addition, Mr. Krenn advises boards of directors on governance and compliance matters.
Mr. Krenn has represented clients in a broad range of industries, including biopharmaceutical, medical device, e commerce, cybersecurity, software, internet, social media, semiconductor, unmanned aerial vehicles, agtech, consumer products, finance, cleantech, energy and action sports.
Mr. Krenn was recognized as “Best of the Bar” by the San Diego Business Journal in 2015. Mr. Krenn received his J.D., cum laude, from Harvard Law School, where he was a member of the Harvard Association of Law & Business. Mr. Krenn received his B.B.A., summa cum laude, in finance from the University of Notre Dame, where he was a recipient of the Hamilton Finance Award as the senior finance major with the highest GPA and the Eugene D. Fanning Award for exceptional achievement in business communication.
Astute Medical – Venture Financings
Represented Astute Medical, a medical diagnostic company focusing on high-risk medical conditions and diseases, in over $170 million of equity and debt financings.
Mitchell International – Acquisition of Cogent Works
Represented Mitchell International in its acquisition of Cogent Works, a provider of pharmacy network and benefit management services, for an undisclosed sum.
Forward Ventures – Venture Investments and M&A Transactions
Represented Forward Ventures as an investor in multiple equity financings, convertible debt financings and M&A transactions, including transactions involving HemaQuest Pharmaceuticals, LigoCyte Pharmaceuticals, Ambit Biosciences and Syndax Pharmaceuticals.
EvoNexus –Corporate Matters and Portfolio Companies
Represented EvoNexus, the leading technology incubator and hub for Southern California’s startup community, in corporate matters and regularly advises EvoNexus portfolio companies.
Mentor – Sale to Johnson & Johnson
Represented Mentor, a leading supplier of medical products for the global aesthetic market, in its $1.12 billion acquisition by Johnson & Johnson (NYSE: JNJ).
Solarflare Communications – Venture Financings
Represented Solarflare Communications, a provider of application-intelligent networking I/O software and hardware platforms, in over $180 million of equity and debt financings.
Inovio Pharmaceuticals – Registered Direct Offering
Represented Inovio Pharmaceuticals (NASDAQ: INO), a developer of active DNA immunotherapies and vaccines and delivery devices to prevent and treat cancers and infectious diseases, in its $30 million registered direct offering.
Oak Investment Partners – Venture Investments
Represented Oak Investment Partners as an investor in multiple equity financings, including MobiTV and Brit Media.
John Deere – Announced Acquisition of Precision Planning Unit from Monstanto
Represented John Deere (NYSE: DE) in its announced acquisition of the precision planning unit of Monsanto (NYSE: MON) for an undisclosed sum.
Adicet Bio – Venture Financing and Cross-Border Acquisition
Represented Adicet Bio, a biopharmaceutical company focused on the development of next-generation cell immunotherapies, in its Series A financing of up to $53 million and cross-border acquisition of Applied Immune Technologies for an undisclosed sum.
Greenoaks Capital Partners – Venture Investments and Secondary Transactions
Represented Greenoaks Capital Partners and its affiliates as investors in over $100 million in equity financings, debt financings and secondary transactions, including Coupang and several other prominent e-commerce companies.
Gizmo5 Technologies – Sale to Google
Represented Gizmo5 Technologies, a provider of Internet-based calling software for mobile phones and computers, in its sale to Google for an undisclosed sum.
B. Riley Financial – Merger and Financing
Represented B. Riley Financial (NASDAQ: RILY) (formerly Great American Group, Inc.) in its $53 million private placement and merger with investment banking firm B. Riley & Co.
Aspyrian Therapeutics – Venture Financings
Represented Aspyrian Therapeutics, a biotechnology company developing a new class of precision targeted oncologic drugs, in over $50 million of equity financings.
Cogent – Sale to 3M
Represented Cogent, a biometric identification solutions provider, in its $943 million acquisition by 3M (NYSE: MMM).
Western Digital Capital – Venture Investments
Represented Western Digital Capital as an investor in multiple equity financings, including investments in Hightail and Upthere.
ACEA Biosciences – Venture Financings
Represented ACEA Biosciences, a developer of cell analysis instrumentation technologies, in its $30 million Series E Preferred Stock financing.
Netlist – Registered Direct Offering
Represented Netlist (NASDAQ: NLST), a producer of next generation persistent memory solutions, in its $10 million registered direct offering.
Wavestream – Sale to Spacenet
Represented Wavestream, a provider of high power solid state amplifiers, in its $137 million sale to Spacenet, a subsidiary of Gilat Satellite Networks (NASDAQ: GILT).
VoloAgri – Venture Financings
Represented VoloAgri, an agriculture technology company focused on seed genetics, in its $56 million Series B Preferred Stock financing.
OncoSec – Registered Direct Offering
Represented OncoSec (NASDAQ: ONCS), a developer of DNA-based intratumoral cancer immunotherapies, in its $10 million registered direct offering.
Alaska Energy & Resources Company – Sale to Avista
Represented Alaska Energy & Resources Company in its $170 million acquisition by Avista (NYSE).
©1996-2016 Morrison & Foerster LLP. All rights reserved.